DrugPatentWatch Database Preview
Details for Patent: 8,633,309
Email this page to a colleague
Which drugs does patent 8,633,309 protect, and when does it expire?
Patent 8,633,309 protects HARVONI, SOVALDI, EPCLUSA, and VOSEVI, and is included in six NDAs.
Protection for HARVONI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and seventy-five patent family members in thirty-eight countries.
Summary for Patent: 8,633,309
| Title: | Nucleoside phosphoramidates |
| Abstract: | Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. |
| Inventor(s): | Ross; Bruce (El Granada, CA), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (San Ramon, CA), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (San Jose, CA), Chun; Byoung-Kwon (Robbinsville, NJ), Wang; Peiyuan (Totowa, NJ) |
| Assignee: | Gilead Pharmasset LLC (Foster City, CA) |
| Application Number: | 13/738,425 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,633,309 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Recent additions to Drugs Protected by US Patent 8,633,309
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 8,633,309
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-001 | Aug 28, 2019 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-002 | Aug 28, 2019 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| Gilead Sciences Inc | SOVALDI | sofosbuvir | PELLETS;ORAL | 212480-001 | Aug 28, 2019 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| Gilead Sciences Inc | SOVALDI | sofosbuvir | PELLETS;ORAL | 212480-002 | Aug 28, 2019 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | TABLET;ORAL | 208341-002 | Mar 19, 2020 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,633,309
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 3515 | ⤷ Try it Free | |||
| Argentina | 080819 | ⤷ Try it Free | |||
| Argentina | 080870 | ⤷ Try it Free | |||
| Argentina | 081813 | ⤷ Try it Free | |||
| Argentina | 082937 | ⤷ Try it Free | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
